August 2, 2004
New Study Shows that Albumin Strongly Improves Outcomes
Versus Saline in Patients with Subarachnoid Hemorrhage
The IVIG Supply Index represents on-hand supply at the nation's largest distributor of
fractionated plasma products.

From Bayer
Bayer Biological Products Announces Latest Efforts To Combat Product Tampering And Counterfeiting  LINK...

From The California Legislature:
Proposed Drug Pedigree Bill
Fact Sheet for SB 1307: Protection
against counterfeit ("fake") and
adulterated prescription drugs  LINK...
[Editor's note: This bill is scheduled to go
before the CA Assembly Appropriations
Committee on August 4.]

From Octapharma
S.A.F.E. Study: Increasing Confidence
for the Use of Albumin in Intensive
Care Patients  LINK...

Aventis Pasteur Adult Td Vaccine
Now Available from FFF

FFF Enterprises is pleased to announce that we now distribute Aventis Pasteur Adult Td, Tetanus and Diphtheria Toxoids Vaccine, our newest offering from our Responsible Distribution Channel. The vaccine is available at $105.10 per 5 mL vial (10 doses at
0.5 mL each).

Administered by intramuscular injection,
the vaccine is a sterile suspension of
alum-precipitated toxoid that provides simultaneous immunization against tetanus and diphtheria in children seven years of age or older and adults. For anyone not previously immunized in a vaccine series, Td is given in a three-dose sequence. To maintain adequate protection, a booster dose of
0.5 mL is given every 10 years.

In addition to routine immunization, Td is used in recall injection after injury, according to the guidelines for tetanus prophylaxis in routine wound management.

You can place your Td order in any of three easy ways:
  • Call FFF Wow! Customer Care
    at 800-843-7477
  • Visit FFF's BioSupply online ordering at www.fffenterprises.com
  • Fax your order to 800-418-4333
Thank you for supporting FFF' s Guaranteed Channel Integrity.









New Study Shows that Albumin Strongly Improves Outcomes
Versus Saline in Patients with Subarachnoid Hemorrhage

Administration of albumin instead of normal saline yielded a superior three-month outcome, including a strong trend for reduced in-hospital mortality in patients with subarachnoid hemorrhage (SAH) who failed to respond to an initial infusion of 500 mL of saline to elevate central venous pressure.

This study by a team of critical-care specialists and neurosurgeons at University Hospitals of Cleveland evaluated 37 patients, admitted between May 1998 and May 1999, who were infused with 5% or 25% albumin to treat symptomatic vasospasm. These 37 patients, a subset of 63 consecutive SAH patients, failed to respond to a bolus of 500 mL of saline to elevate their central venous pressure (CVP) to
>8 mm Hg. The other 26 patients received only the 500 mL saline bolus.

The outcomes of the subset 37 patients were compared with 47 additional patients, treated between June 1999 and May 2000, who would have received albumin under
the standard protocol, but instead were given large additional saline volume to try to achieve the target CVP. In May 1999, University Hospitals restricted access to albumin in reaction to a flawed and now-discredited1 meta-analysis suggesting an association between albumin use and mortality in critically ill patients.2

This investigation was prompted in part by several recent...
1 The SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the
intensive care unit. N Engl J Med 2004; 350:2247-56.
2 Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients:
systematic review of randomized controlled trials. BMJ 1998; 317:235-40.
Visit fffenterprises.com BioSupply Trends is published by FFF Enterprises, the nation's most trusted distributor of biopharmaceuticals, plasma products and vaccines. FFF Enterprises is accelerating the availability of products, from development to delivery. Contact FFF Enterprises at www.fffenterprises.com or 800-843-7477.

I want to receive BioSupply Trends
I want to stop receiving BioSupply Trends
I want to report technical trouble with BioSupply Trends
I have a question BioSupply Trends
©2004 FFF Enterprises Inc.  
Top of Page